3.13
+0.04(+1.29%)
Currency In USD
| Previous Close | 3.09 |
| Open | 3.2 |
| Day High | 3.45 |
| Day Low | 3.1 |
| 52-Week High | 20 |
| 52-Week Low | 2.6 |
| Volume | 69,751 |
| Average Volume | 54,224 |
| Market Cap | 5.98M |
| PE | -0.12 |
| EPS | -25.59 |
| Moving Average 50 Days | 4.95 |
| Moving Average 200 Days | 5.1 |
| Change | 0.04 |
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
GlobeNewswire Inc.
Jan 12, 2026 1:30 PM GMT
Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement Offerings priced at-the-market under Nasdaq rules ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX” or “Company”)
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
GlobeNewswire Inc.
Dec 22, 2025 3:15 PM GMT
- Halneuron® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 - - The overall study dropout rate of ~4.4% is far below rates typically observed with other FDA approved c
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer Patients
GlobeNewswire Inc.
Sep 29, 2025 11:15 AM GMT
-A first-in-class LRP1 agonist, SP16 phase 1b Chemotherapy Induced Neuropathy (CIPN) Study fully funded by the National Cancer Institute, with projected patient enrollment beginning in the first half of 2026- -SP16 has demonstrated both anti-inflamma